Czechia· CZ-0210037
SYLVANT
A siltuximab product containing siltuximab, registered in Czechia by Recordati Netherlands B.V., Schiphol-Rijk. The same ATC class is registered in 14 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Siltuximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC11 (siltuximab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Siltuximab · ATC L04AC11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- SILTUXIMAB
- Manufacturer
- Recordati Netherlands B.V., Schiphol-Rijk
- Country
- Czechia (CZ)
- ATC code
- L04AC11
- ATC class
- Siltuximab
- Defined daily dose
- 37 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02100371CZK 14353.37
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
151 interactions on record for siltuximab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Siltuximab · interactions on record
151 records
- 28 severe
- 116 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Siltuximab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSYLVANTRecordati Netherlands B.V.
- SwitzerlandSylvant 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMedius AG
- SpainSYLVANT 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- United KingdomSylvant 100mg powder for concentrate for solution for infusion vialsRecordati UK Ltd
- IrelandSYLVANT 100 mg powder for concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
- IcelandSylvantRecordati Netherlands B.V.
- NorwaySylvantRecordati Netherlands B.V.
- PolandSylvantRecordati Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sylvant
- Liechtenstein · Sylvant
- Norway · Sylvant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0d59e6a-9624-4a5c-baeb-b0143c5ed6cd GET /v1/drugs/c0d59e6a-9624-4a5c-baeb-b0143c5ed6cd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "100MG",
"pack_size": "1",
"substance": "SILTUXIMAB",
"cz_kod_sukl": "0210037",
"product_type": "BT",
"substance_codes": "18482",
"registration_state": "R",
"registration_number": "EU/1/14/928/001"
}See everything about siltuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.